Tackling Chronic Liver Disease

CRV431 MOA

Client: Hepion Pharmaceuticals

DESCRIPTION

Non-alcoholic steatohepatitis (NASH) is a chronic fatty liver disease driven by a complex network of molecules called cyclophilins. Cyclophilins A, B, and D regulate disease processes such as mitochondrial damage, inflammation, and fibrosis of liver cells.

Hepion Pharmaceutical’s lead oral drug candidate, CRV431, targets all three cyclophilins by blocking their attachment to cell receptors. The goal of this animation is to educate their patients about the science and versatility of their drug.

Silver Award

Telly Awards – Non-Broadcast; Pharmaceuticals

See also

Lenabasum

PTX-367

The Role of IL-1 alpha in Inflammation

 
 

Our pride and reputation are in everything we deliver.

Visit our process page to see how our award winning animations get created.